diphtheria + tetanus + acellular pertussis + haemophilus influenzae type b combined vaccine

The **diphtheria + tetanus + acellular pertussis + haemophilus influenzae type b combined vaccine** (DTaP-Hib) is an investigational tetravalent combination vaccine developed by **Beijing Zhifei Lvzhu Biopharmaceutical**, a subsidiary of Chongqing Zhifei Biological Products. This biologic product is designed to provide active immunization against four major pediatric pathogens: *Corynebacterium diphtheriae*, *Clostridium tetani*, *Bordetella pertussis*, and *Haemophilus influenzae* type b (Hib). The vaccine formulation typically includes diphtheria and tetanus toxoids, acellular pertussis antigens (such as pertussis toxoid and filamentous hemagglutinin), and a purified Hib capsular polysaccharide conjugated to a carrier protein, all adsorbed onto an aluminum hydroxide adjuvant to enhance immunogenicity. It is currently being evaluated in Phase I clinical trials in China (e.g., CTR20260906) to assess its safety, tolerability, and immunogenicity in infants, toddlers, and children, often using the approved pentavalent vaccine Pentaxim as an active comparator.

Other names

DTaP-Hib combined vaccineAdsorbed acellular diphtheria-tetanus-pertussis and Haemophilus influenzae type b combined vaccineDTaP-Hib vaccine